ClinicalTrials.gg
TerminatedNCT00573157Updated Mar 23, 2016Results posted

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

A Phase 2/3 interventional study of Atacicept and Mycophenolate mofetil in Lupus Nephritis, sponsored by EMD Serono. Terminated at 20 sites in 5 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-03-23.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated due to unanticipated safety issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
83rd of 100
6 · median 50
Started
2007
with 1 other
Phase 2/3
Only one
of the 114
Registered
12th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 83rd largest by enrollment of the 100 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 2/3, and was the 12th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn whether atacicept treatment leads to improvement in kidney function in subjects with active lupus nephritis in combination with mycophenolate mofetil (MMF) and corticosteroids. The study was sponsored by Merck Serono International; operational oversight was provided by ZymoGenetics.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • nephritis
  • atacicept
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of systemic lupus erythematosus (SLE) satisfying at least 4 out of the 11 American College of Rheumatology (ACR) criteria (Appendix B)
  • Renal performed consistent with active International Society of Nephrology/Renal Pathology Society (ISN/PRS) class III or IV lupus nephritis

Exclusion criteria

Exclusion Criteria:

  • Estimated (GFR) less than or equal to (\<=) 30 milliliter per minute (mL/min) per 1.73 square meter (m\^2)
  • Active central nervous system SLE deemed to be severe or progressive and/or associated with significant cognitive impairment
  • Any treatment with MMF, azathioprine, or cyclophosphamide within the last 6 months, or known to MMF or atacicept.
  • Any prior treatment with abatacept, rituximab, belimumab, or other B cell modulating agents.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Atacicept Plus Mycophenolate mofetil Plus Corticosteroids

    Drug: Atacicept · Drug: Mycophenolate mofetil · Drug: Corticosteroids

  • Placebo comparator
    Placebo Plus Mycophenolate mofetil Plus Corticosteroids

    Drug: Mycophenolate mofetil · Drug: Placebo · Drug: Corticosteroids

Interventions

  • DrugTACI receptor-IgG Fc fragment fusion proteinStudies of TACI receptor-IgG Fc fragment fusion proteinTACI receptor-IgG Fc fragment fusion protein pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.

  • DrugPlacebo

    Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.

  • DrugCorticosteroids

    High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed Complete Renal Response (CRR), Partial Response, and Non-response

    Complete renal response (CRR): from baseline, a return to within 10% of normal for renal function (assessed by calculated glomerular filtration rate \[GFR\]), improvement in proteinuria (urine protein/creatinine ratio \<0.5) \& resolution of hematuria. Partial response (PR): from baseline, a \<= 10% worsening in renal function ( by calculated GFR); 50% improvement in proteinuria (assessed by urine protein/creatinine ratio) \& resolution of hematuria, Non-response (NR): Neither criteria for CR or PR was met. Subjects were also deemed NR if they had treatment failure, regardless of CR or PR status. Subjects cannot be treatment failures. A response of CRR was confirmed if the Week 52 value is CRRand if the Week 48 value is CRR and at least 4 weeks apart from Week 52 /if the Week 48 value was missing/ less than 4 weeks from Week 52, then the Week 56 response must be CRR - if the Week 52 value was missing, then Week 48 and Week 56 must be CRR.

    Time frame: At Week 52

Secondary outcomes

  1. Percentage of Participants With Normalization of Renal Function

    Time frame: At Week 52

  2. Number of Participants With New Lupus Flares

    Time frame: At Week 52

07

Results

Posted Mar 23, 2016
Limitations and caveats
The study was terminated due to unanticipated safety issues.

Participant flow

Participant flow — Overall Study
MilestoneAtacicept Plus Mycophenolate Mofetil Plus CorticosteroidsPlacebo Plus Mycophenolate Mofetil Plus Corticosteroids
Started42
Completed00
Not completed42
Withdrew: Adverse event31
Withdrew: Other11

Outcome measures

PrimaryPercentage of Participants With Confirmed Complete Renal Response (CRR), Partial Response, and Non-response

Complete renal response (CRR): from baseline, a return to within 10% of normal for renal function (assessed by calculated glomerular filtration rate \[GFR\]), improvement in proteinuria (urine protein/creatinine ratio \<0.5) \& resolution of hematuria. Partial response (PR): from baseline, a \<= 10% worsening in renal function ( by calculated GFR); 50% improvement in proteinuria (assessed by urine protein/creatinine ratio) \& resolution of hematuria, Non-response (NR): Neither criteria for CR or PR was met. Subjects were also deemed NR if they had treatment failure, regardless of CR or PR status. Subjects cannot be treatment failures. A response of CRR was confirmed if the Week 52 value is CRRand if the Week 48 value is CRR and at least 4 weeks apart from Week 52 /if the Week 48 value was missing/ less than 4 weeks from Week 52, then the Week 56 response must be CRR - if the Week 52 value was missing, then Week 48 and Week 56 must be CRR.

Time frame:
At Week 52

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Normalization of Renal Function
Time frame:
At Week 52

No measurements were reported for this outcome.

SecondaryNumber of Participants With New Lupus Flares
Time frame:
At Week 52

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of trial medication to 24-Week follow-up after last dose of trial medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atacicept Plus Mycophenolate Mofetil Plus Corticosteroids—3/4 (75%)4/4 (100%)
Placebo Plus Mycophenolate Mofetil Plus Corticosteroids—0/2 (0%)1/2 (50%)
Most frequent serious events
Most frequent serious events
EventAtacicept Plus Mycophenolate Mofetil Plus CorticosteroidsPlacebo Plus Mycophenolate Mofetil Plus Corticosteroids
PneumothoraxRespiratory, thoracic and mediastinal disorders1/40/2
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/40/2
SyncopeNervous system disorders1/40/2
AnaemiaBlood and lymphatic system disorders1/40/2
EmpyemaInfections and infestations1/40/2
PneumoniaInfections and infestations1/40/2
Pneumonia legionellaInfections and infestations1/40/2
SepsisInfections and infestations1/40/2
Renal failure acuteRenal and urinary disorders1/40/2
Hypertensive crisisVascular disorders1/40/2
Most frequent other events
Showing 10 of 44
Most frequent other events
EventAtacicept Plus Mycophenolate Mofetil Plus CorticosteroidsPlacebo Plus Mycophenolate Mofetil Plus Corticosteroids
NauseaGastrointestinal disorders1/41/2
Abdominal painGastrointestinal disorders0/41/2
Injection site haematomaGeneral disorders0/41/2
HypokalaemiaMetabolism and nutrition disorders2/40/2
TachycardiaCardiac disorders1/41/2
PalpitationsCardiac disorders0/41/2
HypogammaglobulinaemiaImmune system disorders2/40/2
ArthralgiaMusculoskeletal and connective tissue disorders0/41/2
DysgeusiaNervous system disorders0/41/2
Leukocytoclastic vasculitisSkin and subcutaneous tissue disorders0/41/2

Baseline characteristics

Baseline analysis population included all the participants randomized in the trial.

Age, Continuous
Age, Continuous(years)Atacicept Plus Mycophenolate Mofetil Plus CorticosteroidsPlacebo Plus Mycophenolate Mofetil Plus CorticosteroidsTotal
Mean36.8 ± 11.336.0 ± 25.536.5 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)Atacicept Plus Mycophenolate Mofetil Plus CorticosteroidsPlacebo Plus Mycophenolate Mofetil Plus CorticosteroidsTotal
Female314
Male112
08

Study locations

20 sites
  • Tulane University Hospital and Clinic Department of Internal Medicine
    New Orleans,, Louisiana, United States
  • Northwest Louisiana Nephrology Research
    Shreveport, Louisiana 71101, United States
  • Wayne State University Lupus Database Departments of Internal Medicine and Obstetrics & Gynecology Division of Rheumatology Wayne State University School of Medicine
    Detroit, Michigan, United States
  • The Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • Seligman Center for Advanced Therapeutics
    New York, New York 10003, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27109, United States
  • Rheumatology Clinical Research Unit, Division of Rheumatology University Hospitals Case Medical Center
    Beachwood, Ohio 44122, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Southwest Rheumatology and Research Group, LLC
    Middleburg Heights, Ohio 44130, United States
  • 1711 St. Julian Place
    Columbia, South Carolina 29204, United States
  • ACME Research, LLC
    Orangeburg, South Carolina 29118, United States
  • Institute of Rheumatology
    Prague, 128 50, Czech Republic
  • Hospital Sultanah Bahiyah
    Kedah, Malaysia
  • Hospital University Kebangsaan Malaysia
    Kuala Lumpur, Malaysia
  • University of Malaya Medical Centre
    Kuala Lumpur, Malaysia
  • Hospital Pulau Pinang
    Pulau Pinang, Malaysia
  • Changi General Hospital
    Singapore, Singapore
  • Singapore General Hospital
    Singapore, Singapore
  • Kaohsiung Veterans General Hospital
    Kaohsiung, Taiwan
09

References and documents

Publications

  • Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012 Feb 7;14(1):R33. doi: 10.1186/ar3738. PubMed 22325903 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 6 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2007
First posted
Dec 14, 2007
Start
Dec 2007
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Mar 23, 2016
Last update
Mar 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00573157
Lead sponsor
EMD Serono
Collaborators
ZymoGenetics
Responsible party
Sponsor
First posted
Dec 14, 2007
Start date
Dec 2007
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Mar 23, 2016
Last update
Mar 23, 2016

Study contacts

Medical Responsible
study director · EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion